# Shaperon jobs and careers

> 0 open roles at Shaperon as of October 23, 2026. Source: https://www.thejobsmap.com/company/shaperon

Shaperon is a clinical stage biotech company developing novel inflammasome inhibitors(small molecule). Its unique mechanism of action of GPCR-regulated P2X7 inhibition suppresses a broad spectrum of inflammatory cytokines including IL-1β, IL-18, IL-6, and TNF-α, etc. by controlling both priming and activation phase of inflammasome, whereas conventional approaches are designed to suppress only the activation phase. With this unique and novel modality which is best suited to address complex immune-mediated inflammatory disorders, we are currently developing multiple clinical programs in atopic dermatitis, cytokine release syndrome, Alzheimer’s disease, ulcerative colitis, NASH, etc. In addition to inflammasome R&D programs, Shaperon has anti-viral, anti-cancer nanobody therapeutics. Shaperon’s proprietary immunized nanobody libraries combined with high throughput screening and in vitro/in vivo system enable us to fast forward the realization of advantages of Nanobodies over conventional antibody-based medicines. We currently developing multi-valent, multi-specific Nanobodies in multiple delivery forms in oncology and viral infection diseases.

## Key facts

| | |
|---|---|
| Open roles | 0 |
| Founded | 2008 |
| Employees | 11 to 50 |
| Total funding | $26B |
| Industries | Biopharma, Biotechnology |
| Website | https://shaperon.com |

## Leadership

- Jong Eun Lee, Chief Business Officer

## Common questions

### Is Shaperon hiring right now?

Shaperon has no open roles listed as of October 23, 2026. Roles appear here as soon as they are posted on Shaperon's careers site.

### Who leads Shaperon?

Jong Eun Lee, Chief Business Officer, is at the top of Shaperon's org chart.

### How do I apply for a job at Shaperon?

Pick a role on Shaperon's TheJobsMap page and select Apply. Every listing links to the original posting on Shaperon's own careers site, so you apply directly with the employer.